CA2018566A1 - Purification of q beta replicase - Google Patents
Purification of q beta replicaseInfo
- Publication number
- CA2018566A1 CA2018566A1 CA002018566A CA2018566A CA2018566A1 CA 2018566 A1 CA2018566 A1 CA 2018566A1 CA 002018566 A CA002018566 A CA 002018566A CA 2018566 A CA2018566 A CA 2018566A CA 2018566 A1 CA2018566 A1 CA 2018566A1
- Authority
- CA
- Canada
- Prior art keywords
- beta replicase
- resin
- beta
- replicase
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010066717 Q beta Replicase Proteins 0.000 title claims abstract description 108
- 238000000746 purification Methods 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000011347 resin Substances 0.000 claims description 38
- 229920005989 resin Polymers 0.000 claims description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 229920002684 Sepharose Polymers 0.000 claims description 19
- 239000013592 cell lysate Substances 0.000 claims description 15
- 229920002873 Polyethylenimine Polymers 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 8
- 125000002091 cationic group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000000527 sonication Methods 0.000 claims description 4
- 238000000265 homogenisation Methods 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 41
- 102000004190 Enzymes Human genes 0.000 description 41
- 229940088598 enzyme Drugs 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 36
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 16
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VHTUHGNVVZPWGO-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethyl-8-(pyridin-3-ylmethyl)purine-2,6-dione Chemical compound OCCN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1CC1=CC=CN=C1 VHTUHGNVVZPWGO-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241001534160 Escherichia virus Qbeta Species 0.000 description 2
- 108010025076 Holoenzymes Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 streptomycin sulfate Chemical class 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100021309 Elongation factor Ts, mitochondrial Human genes 0.000 description 1
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 108010063460 elongation factor T Proteins 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
PURIFICATION OF Q BETA REPLICASE
Abstract of the Disclosure A process of producing highly pure, Q Beta replicase having a high level of activity is described. The present process allows isolation of Q Beta replicase from recombinant bacteria containing a clone of a phage DNA
encoding the 65,000 weight subunit of Q Beta replicase.
The present process provides an efficient method for producing pure Q Beta replicase which can readily be scaled up to commercial production levels.
Abstract of the Disclosure A process of producing highly pure, Q Beta replicase having a high level of activity is described. The present process allows isolation of Q Beta replicase from recombinant bacteria containing a clone of a phage DNA
encoding the 65,000 weight subunit of Q Beta replicase.
The present process provides an efficient method for producing pure Q Beta replicase which can readily be scaled up to commercial production levels.
Description
201~6 I , .
PURIFICATION OF Q BETA REPLICASE
Descri~tio_ '`. ;~,'~ ~
B_c_~ro_nd Q Beta replicase is an RNA dependent RNA polymerase ~-05 that is produced in E._coli as a result of infection by the bacteriophage Q Beta. Q Beta replicase is composed of one phage-encoded polypeptide of molecular weight 65,000, and three host-encoded polypeptides of molecular weight 70,000, 45,000, and 35,000. These host-encoded 10 polypeptides are, respectively: 30 S ribsomal protein Sl, and protein synthesis elongation factors EF-Tu and EF-Ts.
T. Blumenthal and G. Carmichael, ___. _ev.__ioc_e_., ~-~
48:525-548 (1979).
Q Beta replicase autocatalytically replicates SQme 15 specific types of RNA known as variants i___itro. This ~ `
RNA can be amplified exponentially, to produce quantities -~
of RNA which are then used in bioassays. For example, midivariant (MDV) RNA produced by Q Beta replicase in such an amplification system can be tagged with biotin to 20 form biotinylated RNA which combines with avidin to form --an adduct useful as a reporter for a variety of replication-assisted bioassays for antibodies or nucleic `
acids. B.C.F. Chu et al., __cleic__ci_s_Res., 14:5591 (1986); E.A. Miele et al., J.__ol.__iol., 171:281 (1983).
Q Beta replicase is generally obtained and isolated from Q Beta phage-infected cells. Eoyang and August ;
report a complex scheme for isolating Q Beta replicase ~
which consists of: 1) alumina extraction of bacteriophage ;~
infected cells, 2) polyethylene glycol (PEG)-dextran 30 phase partitioning, 3) ammonium sulfate precipitation, 4) phosphocellulose column chromatography, 5) QAE-Sephadex :~
PURIFICATION OF Q BETA REPLICASE
Descri~tio_ '`. ;~,'~ ~
B_c_~ro_nd Q Beta replicase is an RNA dependent RNA polymerase ~-05 that is produced in E._coli as a result of infection by the bacteriophage Q Beta. Q Beta replicase is composed of one phage-encoded polypeptide of molecular weight 65,000, and three host-encoded polypeptides of molecular weight 70,000, 45,000, and 35,000. These host-encoded 10 polypeptides are, respectively: 30 S ribsomal protein Sl, and protein synthesis elongation factors EF-Tu and EF-Ts.
T. Blumenthal and G. Carmichael, ___. _ev.__ioc_e_., ~-~
48:525-548 (1979).
Q Beta replicase autocatalytically replicates SQme 15 specific types of RNA known as variants i___itro. This ~ `
RNA can be amplified exponentially, to produce quantities -~
of RNA which are then used in bioassays. For example, midivariant (MDV) RNA produced by Q Beta replicase in such an amplification system can be tagged with biotin to 20 form biotinylated RNA which combines with avidin to form --an adduct useful as a reporter for a variety of replication-assisted bioassays for antibodies or nucleic `
acids. B.C.F. Chu et al., __cleic__ci_s_Res., 14:5591 (1986); E.A. Miele et al., J.__ol.__iol., 171:281 (1983).
Q Beta replicase is generally obtained and isolated from Q Beta phage-infected cells. Eoyang and August ;
report a complex scheme for isolating Q Beta replicase ~
which consists of: 1) alumina extraction of bacteriophage ;~
infected cells, 2) polyethylene glycol (PEG)-dextran 30 phase partitioning, 3) ammonium sulfate precipitation, 4) phosphocellulose column chromatography, 5) QAE-Sephadex :~
2 ~ 6 column chromatography, 6) hydroxylapatite column chromatography, and 7) Bio-Gel A-0.5m column chromatography. Eoyang, L. and August, J.L. Pr_c.
Nucleic Acid Res., 2: 829 (1972). Kamen and others also _________________ _ 05 describe schemes for obtaining Q Beta replicase, which are variations of the above. Kamen, R. Bioc_em_Biop_ys.
_c_a, 262: 88-100 (1972); Sumper, N. and Luce, R. _roc.
N_ l.__cad._Sci._US_, 72: 162-166 (1975). Presently-available methods of obtaining Q Beta replicase have several important limitations: the resulting product is not sufficiently pure (i.e., contaminated with MDV 1 RNA), the procedures are complex and labor intensive, and they cannot be readily scaled up to a production level to produce large quantities needed for use in commercial assay systems. The use of alumina éxtraction and PEG-dextran phase partitioning in the initial processing steps places severe limitations on the scale of the process.
:, ..
_ummary of the Invention ~____ _________________ The present invention rela~es to a method or process for purifying Q Beta replicase from cells which produce the enzyme and to highly purified Q Beta replicase, obtained by the present method, which is essentially free of midivariant or other template RNA contamination (i.e., substantially pure Q B replicase). The method is a four-step scheme which consists of: 1) disrupting ~he ~
cells to form a crude cell lysate; 2) contacting the cell lysate with a polymeric agent which selectively precipitates nucleic acids; 3) separating the enzyme by ~ `:
2~18~6~ ;:
Nucleic Acid Res., 2: 829 (1972). Kamen and others also _________________ _ 05 describe schemes for obtaining Q Beta replicase, which are variations of the above. Kamen, R. Bioc_em_Biop_ys.
_c_a, 262: 88-100 (1972); Sumper, N. and Luce, R. _roc.
N_ l.__cad._Sci._US_, 72: 162-166 (1975). Presently-available methods of obtaining Q Beta replicase have several important limitations: the resulting product is not sufficiently pure (i.e., contaminated with MDV 1 RNA), the procedures are complex and labor intensive, and they cannot be readily scaled up to a production level to produce large quantities needed for use in commercial assay systems. The use of alumina éxtraction and PEG-dextran phase partitioning in the initial processing steps places severe limitations on the scale of the process.
:, ..
_ummary of the Invention ~____ _________________ The present invention rela~es to a method or process for purifying Q Beta replicase from cells which produce the enzyme and to highly purified Q Beta replicase, obtained by the present method, which is essentially free of midivariant or other template RNA contamination (i.e., substantially pure Q B replicase). The method is a four-step scheme which consists of: 1) disrupting ~he ~
cells to form a crude cell lysate; 2) contacting the cell lysate with a polymeric agent which selectively precipitates nucleic acids; 3) separating the enzyme by ~ `:
2~18~6~ ;:
chromatography; and 4) purifying the enzyme by ~
chromatography. ~:
The sub;ect method has several advantages that presently-available methods do not offer. First, because 05 the subject method includes a step of disrupting the ~ -cells, kilogram amounts of cell paste can be processed. ~ -In contrast, presently-available processes, such as those including alumina extraction, are only useful for small amounts, (i.e., about 100-200 grams) of cell paste, 10 Second, because it includes a precipitation step, the .~ . -present method does not include a PEG-dextran phase partitioning step, which is the major rate limiting step ~:
in other processes. The use of precipitation in the presence of sodium chloride in the present method not 15 only increases the amount of Q Beta replicase that is ` ~`
extracted from the cells, but also eliminates several inhibitors of the enzyme that are present in crude Q Beta replicase extracts made by other processes. Third, through use of the present purification process, high 20 yields of the enzyme result. Fourth, the replicase produced has a high level of specific activity, and nearly homogeneous (nearly pure) enzyme is obtained.
That is, the yield of Q Beta replicase from the present process is nearly 10-fold higher than yields from 25 previously-available methods, the specific activity of the product is nearly 8-fold higher than the specific activity of the product of previously available methods; ~- ~
and Q Beta replicase produced by the present method is `
nearly homogeneous, while enzyme purified by prior art 30 methods is only about 50~ pure. Fifth, the present process is simple and can be readily scaled up. For '. .: , 201~6~
example, it can be used to produce highly purified Q Beta replicase in sufficient quantities for use in a commercial Q Beta amplification system.
Brief Descri~tion o___ e Fi~__es 05 Figure 1 shows an SDS:PAGE gel comparing samples of purified Q Beta replicase. Samples of reduced and denatured Q Beta replicase were run on denaturing lO-15%
polyacrylamide gradient gels, and stained with Coomassie blue. Lane 1: Q Beta replicase purified by the method lO of Eoyang and August, Proc._Nucleic__cid_Res., 2:829 (1972). Lane 2: Q Beta replicase purified by the pre~ent process. Lane 3: Molecular weight markers.
Figure 2 shows denaturing polyacrylamide gel analysis of RNA products synthesized through the use of Q
15 Beta replicase purified by the present process. Lane 1:
0 input molecules; Lane 2: 10 molecules; Lane 3: lO
molecules; Lane 4: lO molecules; and Lane 5:
MDV-FAL-St RNA marker.
Figure 3 shows denaturing polyacrylamide gel of RNA
20 products synthesized by Q Beta replicase purified by the method of Eoyang and August, ibid. Lanes 1 and 2: 0 input molecules; Lane 3: 10 molecules; Lane 4: lO --molecules; Lane 5: 10 molecules; Lane 6: 10 molecules; and Lane 7: MDV-Fal-St.
Figure 4 is a schematic representation of plasmid pTAC QB 6Bp Kan , which contains the Q Beta replicase ~~
gene under the control of the tac promotor. -:
Detailed Descri~tion of the Invention _______________ ________________._____ ,:
The present invention relates to a process or method -30 for purifying Q Beta replicase and to essentially pure or ~
.: :, ,:,::: . ,-.
'2 ~ fi '-homogeneous Q Beta replicase. The present method is useful for obtaining, from cells which produce Q Beta -~
replicase (e.g., cells containing and expressing a recombinant construct, as well as phage-infected cells), 05 Q Beta replicase which is substantially free of contaminants, such as midi-variant RNA, Q Beta RNA or other template. As used herein, Q Beta replicase is said to be "substantially free" of contaminants, if, when it is incubated in standard amplification assay buffer which ~-10 does not contaln any additional RNA template, no -~
detectable RNA synthesis occurs.
The present process has four general steps~
l) disruption of Q Beta replicase-producing cells, to produce a (homogeneous) cell lysate;
2) separation of ~he enzyme from the cell lysate, which is carried out, for example, by contacting the suspension with an amine, such `~
as polyethyleneimine, resulting in precipitation of nucleic acids and nucleic acid processing enzymes bound to them, and, therefore, initial separation of Q Beta replicase from unwanted cellular materials;
3) contact of the supernatant produced in step (2) containing the enzyme with a cationic resin, such as Q Sepharose; and 4) contact of the eluant produced in Step (3) with an anionic resin, such as S Sepharose.
Through use of the present method, Q Beta replicase of greater purity than can be obtained through previously 30 known methods is produced. For example, Q Beta replicase shown to be more than 95% pure, as judged by SDS :
, 201856~
polyacrylamide gel electrophoresis (PAGE~, has been obtained by the present method.
The present process is generally carried out at cold room temperatures (about 4~C) to prevent the enzyme from 05 denaturing, although it is not necessary to do so. In the first step of the present process, cells which produce Q Beta replicase are disrupted. Any cells which ; -produce Q Beta replicase can be used as a source of Q
Beta replicase. For example, the present method can be used to obtain Q Beta replicase from bacterial cells which have been infected with the Q Beta bacteriophage.
Haruna and Spiegelman, Proc. Nat'l Acad._Sci. U.S.A., 54:579-587 (1965). It can also be used to obtain Q Beta replicase from cells which contain a clone of the Q Beta replicase phage subunit, which contains the Q Beta replicase gene under the control of an appropriate -promoter. The present method will now be described as it has been used to purify Q Beta replicase from bacterial cells (E. coli) expressing the cloned gene for the Q Beta replicase phage subunit (constructed by D. Mills, Downstate Medical Center, Brooklyn, NY) under the control of the tac promoter. It is to be understood, however, that the present method can also be used to purify Q Beta --replicase from other cells in which it is produced.
Plasmid pTAC QB 6Bp Kan , which contains the Q Beta replicase gene under the control of the tac promoter is represented schematically in Figure 4. D.R. Mills, J. ~~
_ol. Biol., 200:489-500 (1988), U.S. Patent 4,786,600.
Q Beta replicase-producing cells are suspended in an 30 aqueous medium, such as a buffer (e.g., Tris buffer), and ~-treated to disrupt the cells. Cells can be disrupted by :: :.:. ::
.~,,''' " ~ ,~
'`' ;.~'..
'~ .' ''.~ " ~
, , .
.: . .
:..
2 0 ~ 5 enzymatlc methods (e.g., with lysozyme) or by physical methods. Treatment which physically disrupts the cells is generally by mechanical means, such as sonication or -homogenization. Such treatment causes the cell membrane .~ .
05 to rupture, resulting in release of the contents of the cells into the suspending medium, forming a cell lysate.
In the second step of the present process, nucleic acids in the cell lysate are selectively removed, for example by contacting the lysate with an agent which can .
selectively precipitate the nucleic acids present in the lysate. In this step, the cell lysate is contacted with the agent under conditions sufficient to cause precipitation of nucleic acids and nucleic acid processing enzymes while retaining Q Beta replicase in 15 the supernatant. A particularly useful agent for this :
purpose is polyethylenimine (PEI). However, other agents which precipitate nucleic acids, such as streptomycin sulfate, can be used. The precipitation step is necessary to remove MDV RN~, and other nucleic acids from the cell lysate. Once precipitation is completed, the precipitate containing the PEI and other cell debris -is separated from the mixture, by centrifugation, for example, and discarded. Q Beta replicase is present in the resulting supernatant, which is subsequently treated ;
25 in such a manner, as described below, that substantially ~ :~
pure Q Beta replicase is obtained.
In the third step of the present process, the ~ .
supernatant is diluted as needed (e.g., with a neutral buffer, such as Tris buffer). The diluted material is 30 then applied to a cationic chromatography resin which binds Q Beta replicase enzyme. The resin is generally 2 ~ 6 6 ~. .
contained in a column. Q Sepharose is a particularly useful resin for this purpose. However, other cationic resins, for example, QAE Sephadex, can also be used.
After the enzyme has been loaded onto the resin, the 05 resin is washed with several column volumes of a neutral v , buffer, such as Tris, containing a low concentration of a salt, such as NaCl. Once washing is complete, the enzyme is eluted from the column using a salt gradient, which ranges, for example, from about 100 to about 400 mM NaCl, 10 in Tris buffer. The fractions are collected, and tested for the presence of the enzyme (e.g., by using an activity assay, such as the Poly C assay described in the Exemplification). Fractions are selected in order to minimize contaminants in the product. Preferably, the 15 fracti.ons showing the highest incorporation rate (the "peak activity" fractions) are pooled prior to the fourth :
step.
In the fourth step of the present process, the pooled fractions are contacted with an anionic chroma-20 tography resin. S Sepharose is a particularly usefulresin for this purpose. The resin is preferably contained in a column. The pooled fraction is diluted as ~`~
needed to lower the salt concentration (e.g., with the - -~
Tris buffer) and then loaded onto the resin. Once all of 25 the fraction has been loaded onto the column, the column is washed, and then eluted with a salt gradient, as in - ;-the third step. The eluant is assayed to determine which fractions contain the peak enzyme activity.
Q Beta replicase obtained by this process is 30 substantially homogeneous, and has been 5hown to be free -of MDV RNA and to be more than 95~ pure, as measured by `
~ . ~ ' ' ' --`i 2 ~ 6 .
g ~,-.. -~-.
SDS PAGE. As described below and in the Exemplification, the present method has been used to obtain such -substantially pure Q Beta replicase. The present method :~ .
can also be modified, however, to produce "less pure"
05 enzyme (i.e., Q Beta replicase in combination with a ~ `
limited quantity of other proteins), if desired. This can be effected by changing (shortening) the length of :
the chromatography column used, by increasing the quantity of materials loaded on a column, or by using "step" gradients rather than linear gradients. The process is conducive to scale-up to commercial production levels. The Q Beta replicase recovered from the last step of the method is highly active, and efficiently .
replicates midivariant (MDV) RNA templates in vitro. ~
In one embodiment of the present method, a culture -of E._coli cells infected with Q Beta replicase phage or cells containing a subunit clone of the phage DNA
encoding the 65,000 mw subunit of the enzyme is used.
The E._coli cells were transformed by a plasmid vector 20 which contains the Q Beta replicase gene under the .
control of the tac promoter. The plasmid, designated pTAC QB 6Bp Kan, is shown schematically in Figure 4. E. ~
coli cells transformed by the plasmid produces Q Beta ~ -replicase. D.R. Mills, J. _ol. Biol., 200:489-500 25 (1988). The cells are suspended in a buffer or neutral `~
salt solution which contains 50 mM Tris-HCl (pH 7.8), 55 `~
mM MgC12, 5 mM 2-mercaptoethanol, 1 mN EDTA and 506 mM ~
NaCl. This step, and all of the subsequent steps in the ;~
process are carried out at 4C. The cells are disrupted 30 by subjecting the cell suspension to homogenization, for example, in a Matlin Gaulin homogenizer, to form a crude ".~ :"''; :~::
20~.~5$6 -cell lysate. The lysate is then contacted with 10% (w/v) polyethyleneimine (PEI), causing precipitation of the fraction containing MDV RNA. The precipitats and supernatant (which contains the Q Beta replicase) are 05 separated by centrifugation The supernatant is diluted with a buffer containing 50 mM Tris-HCl (pH 7.8), 5 mM
MgC12, 5 mM 2-mercaptoethanol and 1 mM EDTA. The diluted solution is then contacted with Q Sepharose resin, which binds Q Beta replicase. The column is eluted with a salt 10 gradient containing from about 100 to 400 mM NaCl and the fractions collected and assayed for Q Beta replicase activity. The fractions containing Q Beta replicase are pooled, diluted with the same dilution buffer, and contacted with S Sepharose resin. The Q Beta replicase 15 selectively binds to the S Sepharose resin, thereby making it possible to separate the enzyme from other components. Q Beta replicase is eluted from the resin using a salt gradient, as above. Enzyme is obtained in high purity by this process. ~
The use of PEI precipitation followed by Q Sepharose ~ -and S Sepharose column chromatography produces nearly -homogeneous enzyme. Other procedures require several additional steps to achieve the same level of purity, with a lower overall yield. A comparison of Q Beta 25 replicase produced by the present process to enzyme produced by the process of Eoyang, i_id. and August is ~hown in Table 1. ' ~ ~ :
` :
20~8~66 ~
- 11 - " ', ' ' .' - . .
Comparison of Q Beta Replicase PuriEied by the Method of Eoyang and August Versus Present Method 05ProcessU/ml Total Units m~ml Total m~ U~mg Eoyang and 173 1038 1.2 7.8 144 August Method Present670 20,100 0.59 17.7 1130 lOMethod#
.
Pre.pared from 200 g of phage-infected cells ~
Prepared from 50 g of E._coli that contain the Q Beta phage subunit , gene under the control of the tac promoter .~
~ ' ' ,'.' ~: .'"`
A particularly valuable aspect of this process is 15 that it yields enzyme that is essentially free of MDV 1 . ;~
RNA, whereas replicase purified by the method of Eoyang :
and August is contaminated with MDV 1 RNA. -~
The enzyme obtained through use of the present .
method efficiently replicates Q Beta replicase templates, 20 such as MDV RNA. Thus t the enzyme is useful in bioassay systems (e.g., to produce MDV RNA for use as a reporter group, as described by Chu et al. B.C.F, Chu et al,, Nucleic Acids_Res., 14:5591 (1986)). Q Beta replicase produced by the present process is also useful in systems 25 for amplifying RNA. The present enzyme, which is free of ~ ;~
6 ~
RNA contaminants and can be more than 95% pure (as judged by SDS:PAGE), is particularly useful in amplification and bioassay systems.
The invention is illustrated by the following 05 exemplification, which is not intended to be limiting in any way.
EXEMPLIFICATION
_______________ : , P_rific_tio__o__Q_Bet___e~licase__ro__P__~e I__ecte__E.
Coli_Cells ~.
One hundred (100 g) grams of recombinant E._coli :
cells containing the cloned gene for the Q Beta replicase phage subunit under the control of the t_c promoter was .
used as the source of Q Beta replicase.
The following procedure was carried out in a cold -~
15 room (4C), and in a RNA-free environment, using sterile ~:
buffers to minimize contamination with MDV-l RNA. The E. ~:
coli cells were suspended in a one liter beaker in 2.5 .~ ~;
volumes of a solution containing 50 mM Tris-HCl buffer, ~ :~
(pH 7.8), 55 mN MgC12, 5 mM 2-mercaptoethanol, l mN
20 (ethylenediaminetetraacetic acid) EDTA and 500 mM NaCl.
A clean stir bar was added and the contents of the beaker were stirred at 4C until the suspension was homogeneous. .
One half of the cell suspension was transferred to a Rosett sonicating cell (250 ml Heat Systems-Ultrasonics) ~;
25 and the cell was placed in an ice-water bath. The' ~ .
remainder of the cell suspension was kept on ice.
The cell suspension was sonicated 4 times, 2 minutes ~:
each time, at an output control setting of 7. After each 2 minute interval, the temperature of the suspension ~;
'.,~' '1 20~8566 ~ -': "
increased from 4C to about 10-12C. The cell suspension was allowed to cool down to 6C or less before resuming sonication. After sonication was complete, the volume of the sonicated cell suspension was measured. The 05 suspension was transferred to a clean l L beaker and placed on ice. The procedure was repeated with the remainder of cell suspension.
A clean stir bar was added to the beaker containing sonicated cell suspension and the contents stir~ed on a stir plate at 4C. 0.03 volumes of 10% polyethyleneimine (w/v) (Aldrich) was gradually added to the cell homogenate.
After all the polyethyleneimine was added, the suspension was stirred for an additional 15 minutes.
The contents of the beaker were transferred to two 250 ml polypropylene centrifuge bottles and centrifuged in a sorvall GSA rotor for 30 minutes at 10,000 rpm at ;~
4C. The clear supernatant was removed from the pellet ~.
material. The volume of the supernatant was measured and :
::: :~ .
20 transferred to a clean 2 L beaker. `~
The supernatant was diluted with 4 volumes of the solution of 50 mM Tris- HCl (pH 7.8) 5 mM MgC12, 5 mM
2-mercaptoethanoli 1 mM EDTA, and applied in a ``~
concentration of 30 mg of protein per ml of resin to an :~
25 equilibrated 220 ml Q Sepharose column (Q Sepharose Fast Flow resin, Pharmacia) at a flow rate of 400-450 ml/hr.
A UV-l monitor (Pharmacia, 280 nm filter) was set at a ~~
AUFS of 2.0 and the chart speed of 0.2 mm/min.
While the enzyme was being loaded onto the column, 30 the supernatant fraction was assayed for Q Beta replicase activity using the Poly C assay (described below) 201~6 After all of the enzyme had been loaded onto the column, the column was washed with a solution of 50 mM
Tris-HCl (pH 7.8), 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, and 100 mM NaCl, at a flow rate of 400-450 05 ml/hr. The column was washed until the UV absorbance decreased to less than 0.4 (4-6 column volumes).
A 10 column-volume (2 x 1100 ml) gradient was -prepared ranging from 100-400 mM NaCl in 50 mM Tris-HCl ~ -(pH 7.8), 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, -10 and the gradient was run at a flow rate of 200-225 ml/hr.
Fractions of 22 ml were collec~ed. The chart speed of the recorder was increased to 0.5 mm/min. i~
To minimize the risk of contaminating the fractions with MDV RNA, 0.1-0.2 ml aliquots of the fractions to be 15 assayed were removed using sterile 1 ml pipettes and transferred to sterile 1.5 ml microcentrifuge tubes.
The Q Sepharose fractions were assayed for Q Beta replicase activity using the Poly C assay.
The peak replicase fractions were assayed for the 20 presence of contaminating RNase, and for activity in the -~;~
absence of any template to determine whether any of the peak fractions contained MDV-l RNA.
The peak Q Beta replicase fractions were determined based on the following criteria~
1) fractions that contain 50~ +/- 5~ of the activity of the maximum fraction;
2) fractions that are free of major RNase ~e~ , contamination; and :
3) fractions that are free of MDV-l RNA ;~
contamination. :
Fractions meeting these criteria were pooled. ~
- - 2 ~ 6 The protein concentration of the fractions were determined using the Bradford Assay. M. Bradford, A_al.
Bioc_e_., 72:248 (1976). Replicase activity was :
determined using the Poly C assay.
05 An S Sepharose (Pharmacia) column was poured and equilibrated with lO column volumns of 50 mM Tris-HCl (pH ~ ~
7.8) 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, and -~ ;
100 mM NaCl.
Once the column was equilibrated, the pooled ; ;-~
fraction was diluted with 2.5 volumes of 50 mM Tris-HCl (pH 7.8) 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA.
The diluted enzyme was applied to the column in a concentration of 10 mg of protein per ml of resin at a flow rate of two column volumes per hour. The UV-l ~
15 monitor was set at an AUFS setting of 0.5 and the chart ~ :
speed at 0.2 mm/min. ~ -.: -:- ::
Once all of the enzyme was applied to the column, the column was washed with 50 mM Tris-HCl (pH 7.8), 5 mM
MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, and 100 mM NaCl and a 10 column volume gradient of 100 mM to 400 mM NaCl was run at a flow rate of 1 column volume per hour. -~
Fractions of 0.01 volume of the total gradient were collected. The chart speed of recorder was increased to 0.5 mm/min.
To minimize the risk of contaminating ~he column fractions with MDV RNA, 0.1 ml aliquots were removed -using sterile 1 ml pipettes and transferred to sterile ~~
1.5 ml microcentrifuge tubes.
The S Sepharose fractions were assayed for replicase 30 activity using the Poly C assay, to define the location of the replicase peak.
... ~:...
,.
2~18~66 To discriminate between the enzyme fractions which contain Q Beta "Holoenzyme" versus those that contain Q
Beta "alpha-less" enzyme which does not have the Sl subunit and cannot replicate MDV RNA templates, aliquots ~--05 of the peak fraction were run on denaturing 10-15~ poly-acrylamide gels using the PhastSystem (Pharmacia).
Fractions containing the highest replicase activity were assayed for the presence of contaminating RNases, and were assayed in the absence of any added template to ~:
10 determine whether any of the peak fraction contained ` ~
MDV-l RNA. ~ `
The "peak" fractions were determined based on the following criteria:
1) fractions that contain at least 33~ +/ -5 of the activity of the maximum fraction;
: ~.: .
2) fractions that contain only Q Beta "Holoenzyme"; -;~
3) fractions that are free of RNase contamination;
and 4) fractions that are free of MDV-l RNA.
Fractions meeting all four of these criteria were pooled. The protein concentration of this fraction was determined using the Bradford Assay. Replicase activity was determined using the Poly C assay.
The fraction was also assayed for replicase activity ; -25 using MDV RNA as a template.
An equal volume of chilled ultra pure glycerol was ;
added to the remainder of the fraction, and mixed gently ~~
until no Schleiren lines were observed.
: : :
Q_Beta_ e~licase__ss_y_ _Poly C Tem~late A reaction mixture was prepared by combining the . ~ "
. .''~
^` 201~66 -following reagents in a 1.5 ml micro-centrifuge tube at ~ .
room temperature~
chromatography. ~:
The sub;ect method has several advantages that presently-available methods do not offer. First, because 05 the subject method includes a step of disrupting the ~ -cells, kilogram amounts of cell paste can be processed. ~ -In contrast, presently-available processes, such as those including alumina extraction, are only useful for small amounts, (i.e., about 100-200 grams) of cell paste, 10 Second, because it includes a precipitation step, the .~ . -present method does not include a PEG-dextran phase partitioning step, which is the major rate limiting step ~:
in other processes. The use of precipitation in the presence of sodium chloride in the present method not 15 only increases the amount of Q Beta replicase that is ` ~`
extracted from the cells, but also eliminates several inhibitors of the enzyme that are present in crude Q Beta replicase extracts made by other processes. Third, through use of the present purification process, high 20 yields of the enzyme result. Fourth, the replicase produced has a high level of specific activity, and nearly homogeneous (nearly pure) enzyme is obtained.
That is, the yield of Q Beta replicase from the present process is nearly 10-fold higher than yields from 25 previously-available methods, the specific activity of the product is nearly 8-fold higher than the specific activity of the product of previously available methods; ~- ~
and Q Beta replicase produced by the present method is `
nearly homogeneous, while enzyme purified by prior art 30 methods is only about 50~ pure. Fifth, the present process is simple and can be readily scaled up. For '. .: , 201~6~
example, it can be used to produce highly purified Q Beta replicase in sufficient quantities for use in a commercial Q Beta amplification system.
Brief Descri~tion o___ e Fi~__es 05 Figure 1 shows an SDS:PAGE gel comparing samples of purified Q Beta replicase. Samples of reduced and denatured Q Beta replicase were run on denaturing lO-15%
polyacrylamide gradient gels, and stained with Coomassie blue. Lane 1: Q Beta replicase purified by the method lO of Eoyang and August, Proc._Nucleic__cid_Res., 2:829 (1972). Lane 2: Q Beta replicase purified by the pre~ent process. Lane 3: Molecular weight markers.
Figure 2 shows denaturing polyacrylamide gel analysis of RNA products synthesized through the use of Q
15 Beta replicase purified by the present process. Lane 1:
0 input molecules; Lane 2: 10 molecules; Lane 3: lO
molecules; Lane 4: lO molecules; and Lane 5:
MDV-FAL-St RNA marker.
Figure 3 shows denaturing polyacrylamide gel of RNA
20 products synthesized by Q Beta replicase purified by the method of Eoyang and August, ibid. Lanes 1 and 2: 0 input molecules; Lane 3: 10 molecules; Lane 4: lO --molecules; Lane 5: 10 molecules; Lane 6: 10 molecules; and Lane 7: MDV-Fal-St.
Figure 4 is a schematic representation of plasmid pTAC QB 6Bp Kan , which contains the Q Beta replicase ~~
gene under the control of the tac promotor. -:
Detailed Descri~tion of the Invention _______________ ________________._____ ,:
The present invention relates to a process or method -30 for purifying Q Beta replicase and to essentially pure or ~
.: :, ,:,::: . ,-.
'2 ~ fi '-homogeneous Q Beta replicase. The present method is useful for obtaining, from cells which produce Q Beta -~
replicase (e.g., cells containing and expressing a recombinant construct, as well as phage-infected cells), 05 Q Beta replicase which is substantially free of contaminants, such as midi-variant RNA, Q Beta RNA or other template. As used herein, Q Beta replicase is said to be "substantially free" of contaminants, if, when it is incubated in standard amplification assay buffer which ~-10 does not contaln any additional RNA template, no -~
detectable RNA synthesis occurs.
The present process has four general steps~
l) disruption of Q Beta replicase-producing cells, to produce a (homogeneous) cell lysate;
2) separation of ~he enzyme from the cell lysate, which is carried out, for example, by contacting the suspension with an amine, such `~
as polyethyleneimine, resulting in precipitation of nucleic acids and nucleic acid processing enzymes bound to them, and, therefore, initial separation of Q Beta replicase from unwanted cellular materials;
3) contact of the supernatant produced in step (2) containing the enzyme with a cationic resin, such as Q Sepharose; and 4) contact of the eluant produced in Step (3) with an anionic resin, such as S Sepharose.
Through use of the present method, Q Beta replicase of greater purity than can be obtained through previously 30 known methods is produced. For example, Q Beta replicase shown to be more than 95% pure, as judged by SDS :
, 201856~
polyacrylamide gel electrophoresis (PAGE~, has been obtained by the present method.
The present process is generally carried out at cold room temperatures (about 4~C) to prevent the enzyme from 05 denaturing, although it is not necessary to do so. In the first step of the present process, cells which produce Q Beta replicase are disrupted. Any cells which ; -produce Q Beta replicase can be used as a source of Q
Beta replicase. For example, the present method can be used to obtain Q Beta replicase from bacterial cells which have been infected with the Q Beta bacteriophage.
Haruna and Spiegelman, Proc. Nat'l Acad._Sci. U.S.A., 54:579-587 (1965). It can also be used to obtain Q Beta replicase from cells which contain a clone of the Q Beta replicase phage subunit, which contains the Q Beta replicase gene under the control of an appropriate -promoter. The present method will now be described as it has been used to purify Q Beta replicase from bacterial cells (E. coli) expressing the cloned gene for the Q Beta replicase phage subunit (constructed by D. Mills, Downstate Medical Center, Brooklyn, NY) under the control of the tac promoter. It is to be understood, however, that the present method can also be used to purify Q Beta --replicase from other cells in which it is produced.
Plasmid pTAC QB 6Bp Kan , which contains the Q Beta replicase gene under the control of the tac promoter is represented schematically in Figure 4. D.R. Mills, J. ~~
_ol. Biol., 200:489-500 (1988), U.S. Patent 4,786,600.
Q Beta replicase-producing cells are suspended in an 30 aqueous medium, such as a buffer (e.g., Tris buffer), and ~-treated to disrupt the cells. Cells can be disrupted by :: :.:. ::
.~,,''' " ~ ,~
'`' ;.~'..
'~ .' ''.~ " ~
, , .
.: . .
:..
2 0 ~ 5 enzymatlc methods (e.g., with lysozyme) or by physical methods. Treatment which physically disrupts the cells is generally by mechanical means, such as sonication or -homogenization. Such treatment causes the cell membrane .~ .
05 to rupture, resulting in release of the contents of the cells into the suspending medium, forming a cell lysate.
In the second step of the present process, nucleic acids in the cell lysate are selectively removed, for example by contacting the lysate with an agent which can .
selectively precipitate the nucleic acids present in the lysate. In this step, the cell lysate is contacted with the agent under conditions sufficient to cause precipitation of nucleic acids and nucleic acid processing enzymes while retaining Q Beta replicase in 15 the supernatant. A particularly useful agent for this :
purpose is polyethylenimine (PEI). However, other agents which precipitate nucleic acids, such as streptomycin sulfate, can be used. The precipitation step is necessary to remove MDV RN~, and other nucleic acids from the cell lysate. Once precipitation is completed, the precipitate containing the PEI and other cell debris -is separated from the mixture, by centrifugation, for example, and discarded. Q Beta replicase is present in the resulting supernatant, which is subsequently treated ;
25 in such a manner, as described below, that substantially ~ :~
pure Q Beta replicase is obtained.
In the third step of the present process, the ~ .
supernatant is diluted as needed (e.g., with a neutral buffer, such as Tris buffer). The diluted material is 30 then applied to a cationic chromatography resin which binds Q Beta replicase enzyme. The resin is generally 2 ~ 6 6 ~. .
contained in a column. Q Sepharose is a particularly useful resin for this purpose. However, other cationic resins, for example, QAE Sephadex, can also be used.
After the enzyme has been loaded onto the resin, the 05 resin is washed with several column volumes of a neutral v , buffer, such as Tris, containing a low concentration of a salt, such as NaCl. Once washing is complete, the enzyme is eluted from the column using a salt gradient, which ranges, for example, from about 100 to about 400 mM NaCl, 10 in Tris buffer. The fractions are collected, and tested for the presence of the enzyme (e.g., by using an activity assay, such as the Poly C assay described in the Exemplification). Fractions are selected in order to minimize contaminants in the product. Preferably, the 15 fracti.ons showing the highest incorporation rate (the "peak activity" fractions) are pooled prior to the fourth :
step.
In the fourth step of the present process, the pooled fractions are contacted with an anionic chroma-20 tography resin. S Sepharose is a particularly usefulresin for this purpose. The resin is preferably contained in a column. The pooled fraction is diluted as ~`~
needed to lower the salt concentration (e.g., with the - -~
Tris buffer) and then loaded onto the resin. Once all of 25 the fraction has been loaded onto the column, the column is washed, and then eluted with a salt gradient, as in - ;-the third step. The eluant is assayed to determine which fractions contain the peak enzyme activity.
Q Beta replicase obtained by this process is 30 substantially homogeneous, and has been 5hown to be free -of MDV RNA and to be more than 95~ pure, as measured by `
~ . ~ ' ' ' --`i 2 ~ 6 .
g ~,-.. -~-.
SDS PAGE. As described below and in the Exemplification, the present method has been used to obtain such -substantially pure Q Beta replicase. The present method :~ .
can also be modified, however, to produce "less pure"
05 enzyme (i.e., Q Beta replicase in combination with a ~ `
limited quantity of other proteins), if desired. This can be effected by changing (shortening) the length of :
the chromatography column used, by increasing the quantity of materials loaded on a column, or by using "step" gradients rather than linear gradients. The process is conducive to scale-up to commercial production levels. The Q Beta replicase recovered from the last step of the method is highly active, and efficiently .
replicates midivariant (MDV) RNA templates in vitro. ~
In one embodiment of the present method, a culture -of E._coli cells infected with Q Beta replicase phage or cells containing a subunit clone of the phage DNA
encoding the 65,000 mw subunit of the enzyme is used.
The E._coli cells were transformed by a plasmid vector 20 which contains the Q Beta replicase gene under the .
control of the tac promoter. The plasmid, designated pTAC QB 6Bp Kan, is shown schematically in Figure 4. E. ~
coli cells transformed by the plasmid produces Q Beta ~ -replicase. D.R. Mills, J. _ol. Biol., 200:489-500 25 (1988). The cells are suspended in a buffer or neutral `~
salt solution which contains 50 mM Tris-HCl (pH 7.8), 55 `~
mM MgC12, 5 mM 2-mercaptoethanol, 1 mN EDTA and 506 mM ~
NaCl. This step, and all of the subsequent steps in the ;~
process are carried out at 4C. The cells are disrupted 30 by subjecting the cell suspension to homogenization, for example, in a Matlin Gaulin homogenizer, to form a crude ".~ :"''; :~::
20~.~5$6 -cell lysate. The lysate is then contacted with 10% (w/v) polyethyleneimine (PEI), causing precipitation of the fraction containing MDV RNA. The precipitats and supernatant (which contains the Q Beta replicase) are 05 separated by centrifugation The supernatant is diluted with a buffer containing 50 mM Tris-HCl (pH 7.8), 5 mM
MgC12, 5 mM 2-mercaptoethanol and 1 mM EDTA. The diluted solution is then contacted with Q Sepharose resin, which binds Q Beta replicase. The column is eluted with a salt 10 gradient containing from about 100 to 400 mM NaCl and the fractions collected and assayed for Q Beta replicase activity. The fractions containing Q Beta replicase are pooled, diluted with the same dilution buffer, and contacted with S Sepharose resin. The Q Beta replicase 15 selectively binds to the S Sepharose resin, thereby making it possible to separate the enzyme from other components. Q Beta replicase is eluted from the resin using a salt gradient, as above. Enzyme is obtained in high purity by this process. ~
The use of PEI precipitation followed by Q Sepharose ~ -and S Sepharose column chromatography produces nearly -homogeneous enzyme. Other procedures require several additional steps to achieve the same level of purity, with a lower overall yield. A comparison of Q Beta 25 replicase produced by the present process to enzyme produced by the process of Eoyang, i_id. and August is ~hown in Table 1. ' ~ ~ :
` :
20~8~66 ~
- 11 - " ', ' ' .' - . .
Comparison of Q Beta Replicase PuriEied by the Method of Eoyang and August Versus Present Method 05ProcessU/ml Total Units m~ml Total m~ U~mg Eoyang and 173 1038 1.2 7.8 144 August Method Present670 20,100 0.59 17.7 1130 lOMethod#
.
Pre.pared from 200 g of phage-infected cells ~
Prepared from 50 g of E._coli that contain the Q Beta phage subunit , gene under the control of the tac promoter .~
~ ' ' ,'.' ~: .'"`
A particularly valuable aspect of this process is 15 that it yields enzyme that is essentially free of MDV 1 . ;~
RNA, whereas replicase purified by the method of Eoyang :
and August is contaminated with MDV 1 RNA. -~
The enzyme obtained through use of the present .
method efficiently replicates Q Beta replicase templates, 20 such as MDV RNA. Thus t the enzyme is useful in bioassay systems (e.g., to produce MDV RNA for use as a reporter group, as described by Chu et al. B.C.F, Chu et al,, Nucleic Acids_Res., 14:5591 (1986)). Q Beta replicase produced by the present process is also useful in systems 25 for amplifying RNA. The present enzyme, which is free of ~ ;~
6 ~
RNA contaminants and can be more than 95% pure (as judged by SDS:PAGE), is particularly useful in amplification and bioassay systems.
The invention is illustrated by the following 05 exemplification, which is not intended to be limiting in any way.
EXEMPLIFICATION
_______________ : , P_rific_tio__o__Q_Bet___e~licase__ro__P__~e I__ecte__E.
Coli_Cells ~.
One hundred (100 g) grams of recombinant E._coli :
cells containing the cloned gene for the Q Beta replicase phage subunit under the control of the t_c promoter was .
used as the source of Q Beta replicase.
The following procedure was carried out in a cold -~
15 room (4C), and in a RNA-free environment, using sterile ~:
buffers to minimize contamination with MDV-l RNA. The E. ~:
coli cells were suspended in a one liter beaker in 2.5 .~ ~;
volumes of a solution containing 50 mM Tris-HCl buffer, ~ :~
(pH 7.8), 55 mN MgC12, 5 mM 2-mercaptoethanol, l mN
20 (ethylenediaminetetraacetic acid) EDTA and 500 mM NaCl.
A clean stir bar was added and the contents of the beaker were stirred at 4C until the suspension was homogeneous. .
One half of the cell suspension was transferred to a Rosett sonicating cell (250 ml Heat Systems-Ultrasonics) ~;
25 and the cell was placed in an ice-water bath. The' ~ .
remainder of the cell suspension was kept on ice.
The cell suspension was sonicated 4 times, 2 minutes ~:
each time, at an output control setting of 7. After each 2 minute interval, the temperature of the suspension ~;
'.,~' '1 20~8566 ~ -': "
increased from 4C to about 10-12C. The cell suspension was allowed to cool down to 6C or less before resuming sonication. After sonication was complete, the volume of the sonicated cell suspension was measured. The 05 suspension was transferred to a clean l L beaker and placed on ice. The procedure was repeated with the remainder of cell suspension.
A clean stir bar was added to the beaker containing sonicated cell suspension and the contents stir~ed on a stir plate at 4C. 0.03 volumes of 10% polyethyleneimine (w/v) (Aldrich) was gradually added to the cell homogenate.
After all the polyethyleneimine was added, the suspension was stirred for an additional 15 minutes.
The contents of the beaker were transferred to two 250 ml polypropylene centrifuge bottles and centrifuged in a sorvall GSA rotor for 30 minutes at 10,000 rpm at ;~
4C. The clear supernatant was removed from the pellet ~.
material. The volume of the supernatant was measured and :
::: :~ .
20 transferred to a clean 2 L beaker. `~
The supernatant was diluted with 4 volumes of the solution of 50 mM Tris- HCl (pH 7.8) 5 mM MgC12, 5 mM
2-mercaptoethanoli 1 mM EDTA, and applied in a ``~
concentration of 30 mg of protein per ml of resin to an :~
25 equilibrated 220 ml Q Sepharose column (Q Sepharose Fast Flow resin, Pharmacia) at a flow rate of 400-450 ml/hr.
A UV-l monitor (Pharmacia, 280 nm filter) was set at a ~~
AUFS of 2.0 and the chart speed of 0.2 mm/min.
While the enzyme was being loaded onto the column, 30 the supernatant fraction was assayed for Q Beta replicase activity using the Poly C assay (described below) 201~6 After all of the enzyme had been loaded onto the column, the column was washed with a solution of 50 mM
Tris-HCl (pH 7.8), 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, and 100 mM NaCl, at a flow rate of 400-450 05 ml/hr. The column was washed until the UV absorbance decreased to less than 0.4 (4-6 column volumes).
A 10 column-volume (2 x 1100 ml) gradient was -prepared ranging from 100-400 mM NaCl in 50 mM Tris-HCl ~ -(pH 7.8), 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, -10 and the gradient was run at a flow rate of 200-225 ml/hr.
Fractions of 22 ml were collec~ed. The chart speed of the recorder was increased to 0.5 mm/min. i~
To minimize the risk of contaminating the fractions with MDV RNA, 0.1-0.2 ml aliquots of the fractions to be 15 assayed were removed using sterile 1 ml pipettes and transferred to sterile 1.5 ml microcentrifuge tubes.
The Q Sepharose fractions were assayed for Q Beta replicase activity using the Poly C assay.
The peak replicase fractions were assayed for the 20 presence of contaminating RNase, and for activity in the -~;~
absence of any template to determine whether any of the peak fractions contained MDV-l RNA.
The peak Q Beta replicase fractions were determined based on the following criteria~
1) fractions that contain 50~ +/- 5~ of the activity of the maximum fraction;
2) fractions that are free of major RNase ~e~ , contamination; and :
3) fractions that are free of MDV-l RNA ;~
contamination. :
Fractions meeting these criteria were pooled. ~
- - 2 ~ 6 The protein concentration of the fractions were determined using the Bradford Assay. M. Bradford, A_al.
Bioc_e_., 72:248 (1976). Replicase activity was :
determined using the Poly C assay.
05 An S Sepharose (Pharmacia) column was poured and equilibrated with lO column volumns of 50 mM Tris-HCl (pH ~ ~
7.8) 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, and -~ ;
100 mM NaCl.
Once the column was equilibrated, the pooled ; ;-~
fraction was diluted with 2.5 volumes of 50 mM Tris-HCl (pH 7.8) 5 mM MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA.
The diluted enzyme was applied to the column in a concentration of 10 mg of protein per ml of resin at a flow rate of two column volumes per hour. The UV-l ~
15 monitor was set at an AUFS setting of 0.5 and the chart ~ :
speed at 0.2 mm/min. ~ -.: -:- ::
Once all of the enzyme was applied to the column, the column was washed with 50 mM Tris-HCl (pH 7.8), 5 mM
MgC12, 5 mM 2-mercaptoethanol, 1 mM EDTA, and 100 mM NaCl and a 10 column volume gradient of 100 mM to 400 mM NaCl was run at a flow rate of 1 column volume per hour. -~
Fractions of 0.01 volume of the total gradient were collected. The chart speed of recorder was increased to 0.5 mm/min.
To minimize the risk of contaminating ~he column fractions with MDV RNA, 0.1 ml aliquots were removed -using sterile 1 ml pipettes and transferred to sterile ~~
1.5 ml microcentrifuge tubes.
The S Sepharose fractions were assayed for replicase 30 activity using the Poly C assay, to define the location of the replicase peak.
... ~:...
,.
2~18~66 To discriminate between the enzyme fractions which contain Q Beta "Holoenzyme" versus those that contain Q
Beta "alpha-less" enzyme which does not have the Sl subunit and cannot replicate MDV RNA templates, aliquots ~--05 of the peak fraction were run on denaturing 10-15~ poly-acrylamide gels using the PhastSystem (Pharmacia).
Fractions containing the highest replicase activity were assayed for the presence of contaminating RNases, and were assayed in the absence of any added template to ~:
10 determine whether any of the peak fraction contained ` ~
MDV-l RNA. ~ `
The "peak" fractions were determined based on the following criteria:
1) fractions that contain at least 33~ +/ -5 of the activity of the maximum fraction;
: ~.: .
2) fractions that contain only Q Beta "Holoenzyme"; -;~
3) fractions that are free of RNase contamination;
and 4) fractions that are free of MDV-l RNA.
Fractions meeting all four of these criteria were pooled. The protein concentration of this fraction was determined using the Bradford Assay. Replicase activity was determined using the Poly C assay.
The fraction was also assayed for replicase activity ; -25 using MDV RNA as a template.
An equal volume of chilled ultra pure glycerol was ;
added to the remainder of the fraction, and mixed gently ~~
until no Schleiren lines were observed.
: : :
Q_Beta_ e~licase__ss_y_ _Poly C Tem~late A reaction mixture was prepared by combining the . ~ "
. .''~
^` 201~66 -following reagents in a 1.5 ml micro-centrifuge tube at ~ .
room temperature~
5 ~1 of 5 X Q beta replicase buffer 5 ~1 of 1.0 mg/ml Poly C (Sigma) .
05 1 ~1 of 10 mM GTP (Pharmacia) 1 ~1 of 50 ~g/ml Rifampicin (Sigma) 0.5 ~1 of alpha- P GTP, 10 ~ Ci/~l (New England Nuclear) 11.5 ~1 DEPC treated water 1 ~1 of enzyme 25 ~1 total volume The 5x Q Beta replicase buffer consisted of 450 mM
Tris-HCl, (pH 7.8), and 70 mM MgC12. ~ :
After all reagents, except the enzyme, had been combined, the tube was vortexed for 10 seconds and then centrifuged at 12,000 x g for 2 seconds to get all of the reagents to the bottom of the tube.
The enzyme was added; the tube was mixed gently and incubated for 10 minutes at 37C.
10 ~1 aliquots were removed from each reaction tube and pipetted onto DE-81 filters (Whatman). The filters were air dried for 1-2 minutes. ~ :
From one of the reaction tubes, 10 ~1 was removed : -and pipetted onto a DE-81 filter, allowed to air dry, placed in a scintillation vial containing 3 ml of water ~~
and counted. From this data the total number of counts :~
that were added to each tube could be determined.
The filters were transferred to a 1 L beaker containing 200 ml of sodium phosphate (500 mM, pH 7.4) - 20~8~6 ' ' ~'' . ' ,.
wash buffer. The filters were washed for 20 minutes at ;
room temperature with occasional shaking. The wash solution was decanted and an additional 200 ml of fresh :-wash buffer solution was added to the beaker and the 05 filters were washed again. The wash step was for 20 minutes. The buffer was removed, and repeated one more time. After the third wash, 200 ml of distilled, deionized water was added to the beaker and the filters were washed for 10 minutes with mixing.
The filters were removed from the water and blotted dry on a piece of Whatman 3 mm paper. ~-The filters were transferred to scintillation vials (Wheaton) containing 3 ml of water.
The vials were capped and the radioactivity in each 15 vial was determined in a scintillation counter at settings for detection of 2 p, 32p, to determine the ~:
level of incorporation by each fraction.
,' '.
Q_Beta_Re~licase_Assay - MDV RNA Tem~late A reaction mixture was prepared by combining the -20 following reagents in a 1.5 ml microcentrifuge tube at room temperature:
5 ~1 of Beta replicase buffer 4 ~1 of a mixture containing 2.5 mM each of ATP, CTP, UTP and GTP (Pharmacia) 1 ~1 of alpha- 2p GTP 10 ~Ci/~l (New England Nuclear) 9 ~1 of DEPC treated water 19 ~1 per assay tube 201856~
. .~.~,. . ..
",~ `'.'': . ~
After the reagents had been combined, the tube was vortexed for 10 seconds and centrifuged at 12,000 x g for 2 seconds to get all of the contents to the bottom of the tube. ~ -05 5 ~1 of an appropriate MDV XNA dilution was added to ~ 5 the above reaction mix. To minimize the risk of contamination, a separate micropipettor was used to dispense the MDV RNA solution. To those reactions where ~ ~
no RNA is added, 5 ~1 of DEPC-treated water was added. ~s 1 ~1 of Q Beta replicase was added to above reaction mix, which was mixed gently and incubated 20 minutes at 37C.
After 20 minutes, 2 ~1 of reaction was removed and added to 18 ~1 of 120 mM NaCl - 20 mM EDTA and placed on ice.
From one of the reaction tubes, 10 ~1 was removed -and pipetted onto DE-81 filter, allowed to air dry, placed in a scintillation vial contain 3 ml of water, and counted. From this data the total number of counts added to each reaction could be determined.
10 ~1 of the 20 ~1 sample from the previous step was pipetted onto a DE-81 filter. The remainder was saved for gel analysis. `
The filters were dried for 1-2 minutes, washed and counted as described above for the Poly C assay.
To analyze amplification reaction products on a denaturing polyacrylamide gel, a 6~ poly-acrylamide-7 M
urea gel was poured and allowed to polymerize. The gel was pre-run at 50 1~ (constant power) for 30 minutes.
1 ~1 of samples were added to 3 ~1 of Formamide-Dye -~
loading buffer. The samples were placed in a boiling 2~18~
-20- ~
water bath for 3 minutes, and transferred to ice until ~ ~`
loading onto gel. -~
The samples were run at 5Q W (constant power) until the Bromphenol Blue marker had run off the gel.
05 The gel was dismantled and p:Laced in a cassette on -~
film (Kodak XAR5) overnight at -70C with an intensifying screen. The film was developed in an automatic film processor. ~ -The activity of Q Beta replicase produced by the .-lOpresent method is summarized in Table 2.
. ~. :
S__m_ry_o_ Q__et_ _e~lic_se_P_ri_icatio_ _r_ctio_ U_its~_l _ot_l___its_~ 1 _ot_l_m~ _~_g Crude Lysate 190 24,700 23.5 3035 8 15Q Sepharose 1013 69,900 4.25 293 238 S Sepharose 670 20,100 0.59 17.7 1130 :
1 U 1 nmol of GMP incorporated in 10 min at 37 Table 2 shows the recovery of enzyme at each step in the purification process (from 50 g of cells).
The enzyme produced by the present method was incubated in standard amplification assay buffer (90 mM ~
Tris-HCl (pH 7.8) and 14 mM MgC12) which did not contain ~~ ;
any added RNA template, and no detectable RNA synthesis was observed after 20 minutes of incubation at 37C
25 (Figure 2, lane 1). MDV-l RNA was not observed even after 60 minutes of incubation.
2 ~ 1 8 ~
, ` .
- -Amplification reactions containing the present enzyme were primed with 10 - 10 MDV-Fal-St molecules, : ;~
(P. M. Lizardi et al., Biotech_olo~y, 6:1197-1202 (1988), and the only product observed was full length MDV-Fal-St ~`
05 (Figure 2, lanes 2-4). However, when enzyme prepared by the method of Eoyang and August was incubated under the same conditions as above, RNA synthesis was observed in the absence of added RNA template, indicating contamination of the enzyme preparation with MDV-l RNA. :
The resulting material was analyzed on a denaturing :
polyacrylamide gel, and as shown in Figure 3, MDV-l RNA
(Figure 3, lanes 1 and 2) was produced. Furthermore, when amplification reactions containing this enzyme were primed with 102 108 MDV-Fal-St molecules, both and ~ :
15 Fal-St MDV-l RNA were synthesized (Figure 3, lanes 3-6). .: -~
Equiv_lents Those skilled in the art will recognize, or be able ~ `~
to ascertain using no more than routine experimentation, -~ ~-many equivalents to the specific embodiments of the ~:
invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
',
05 1 ~1 of 10 mM GTP (Pharmacia) 1 ~1 of 50 ~g/ml Rifampicin (Sigma) 0.5 ~1 of alpha- P GTP, 10 ~ Ci/~l (New England Nuclear) 11.5 ~1 DEPC treated water 1 ~1 of enzyme 25 ~1 total volume The 5x Q Beta replicase buffer consisted of 450 mM
Tris-HCl, (pH 7.8), and 70 mM MgC12. ~ :
After all reagents, except the enzyme, had been combined, the tube was vortexed for 10 seconds and then centrifuged at 12,000 x g for 2 seconds to get all of the reagents to the bottom of the tube.
The enzyme was added; the tube was mixed gently and incubated for 10 minutes at 37C.
10 ~1 aliquots were removed from each reaction tube and pipetted onto DE-81 filters (Whatman). The filters were air dried for 1-2 minutes. ~ :
From one of the reaction tubes, 10 ~1 was removed : -and pipetted onto a DE-81 filter, allowed to air dry, placed in a scintillation vial containing 3 ml of water ~~
and counted. From this data the total number of counts :~
that were added to each tube could be determined.
The filters were transferred to a 1 L beaker containing 200 ml of sodium phosphate (500 mM, pH 7.4) - 20~8~6 ' ' ~'' . ' ,.
wash buffer. The filters were washed for 20 minutes at ;
room temperature with occasional shaking. The wash solution was decanted and an additional 200 ml of fresh :-wash buffer solution was added to the beaker and the 05 filters were washed again. The wash step was for 20 minutes. The buffer was removed, and repeated one more time. After the third wash, 200 ml of distilled, deionized water was added to the beaker and the filters were washed for 10 minutes with mixing.
The filters were removed from the water and blotted dry on a piece of Whatman 3 mm paper. ~-The filters were transferred to scintillation vials (Wheaton) containing 3 ml of water.
The vials were capped and the radioactivity in each 15 vial was determined in a scintillation counter at settings for detection of 2 p, 32p, to determine the ~:
level of incorporation by each fraction.
,' '.
Q_Beta_Re~licase_Assay - MDV RNA Tem~late A reaction mixture was prepared by combining the -20 following reagents in a 1.5 ml microcentrifuge tube at room temperature:
5 ~1 of Beta replicase buffer 4 ~1 of a mixture containing 2.5 mM each of ATP, CTP, UTP and GTP (Pharmacia) 1 ~1 of alpha- 2p GTP 10 ~Ci/~l (New England Nuclear) 9 ~1 of DEPC treated water 19 ~1 per assay tube 201856~
. .~.~,. . ..
",~ `'.'': . ~
After the reagents had been combined, the tube was vortexed for 10 seconds and centrifuged at 12,000 x g for 2 seconds to get all of the contents to the bottom of the tube. ~ -05 5 ~1 of an appropriate MDV XNA dilution was added to ~ 5 the above reaction mix. To minimize the risk of contamination, a separate micropipettor was used to dispense the MDV RNA solution. To those reactions where ~ ~
no RNA is added, 5 ~1 of DEPC-treated water was added. ~s 1 ~1 of Q Beta replicase was added to above reaction mix, which was mixed gently and incubated 20 minutes at 37C.
After 20 minutes, 2 ~1 of reaction was removed and added to 18 ~1 of 120 mM NaCl - 20 mM EDTA and placed on ice.
From one of the reaction tubes, 10 ~1 was removed -and pipetted onto DE-81 filter, allowed to air dry, placed in a scintillation vial contain 3 ml of water, and counted. From this data the total number of counts added to each reaction could be determined.
10 ~1 of the 20 ~1 sample from the previous step was pipetted onto a DE-81 filter. The remainder was saved for gel analysis. `
The filters were dried for 1-2 minutes, washed and counted as described above for the Poly C assay.
To analyze amplification reaction products on a denaturing polyacrylamide gel, a 6~ poly-acrylamide-7 M
urea gel was poured and allowed to polymerize. The gel was pre-run at 50 1~ (constant power) for 30 minutes.
1 ~1 of samples were added to 3 ~1 of Formamide-Dye -~
loading buffer. The samples were placed in a boiling 2~18~
-20- ~
water bath for 3 minutes, and transferred to ice until ~ ~`
loading onto gel. -~
The samples were run at 5Q W (constant power) until the Bromphenol Blue marker had run off the gel.
05 The gel was dismantled and p:Laced in a cassette on -~
film (Kodak XAR5) overnight at -70C with an intensifying screen. The film was developed in an automatic film processor. ~ -The activity of Q Beta replicase produced by the .-lOpresent method is summarized in Table 2.
. ~. :
S__m_ry_o_ Q__et_ _e~lic_se_P_ri_icatio_ _r_ctio_ U_its~_l _ot_l___its_~ 1 _ot_l_m~ _~_g Crude Lysate 190 24,700 23.5 3035 8 15Q Sepharose 1013 69,900 4.25 293 238 S Sepharose 670 20,100 0.59 17.7 1130 :
1 U 1 nmol of GMP incorporated in 10 min at 37 Table 2 shows the recovery of enzyme at each step in the purification process (from 50 g of cells).
The enzyme produced by the present method was incubated in standard amplification assay buffer (90 mM ~
Tris-HCl (pH 7.8) and 14 mM MgC12) which did not contain ~~ ;
any added RNA template, and no detectable RNA synthesis was observed after 20 minutes of incubation at 37C
25 (Figure 2, lane 1). MDV-l RNA was not observed even after 60 minutes of incubation.
2 ~ 1 8 ~
, ` .
- -Amplification reactions containing the present enzyme were primed with 10 - 10 MDV-Fal-St molecules, : ;~
(P. M. Lizardi et al., Biotech_olo~y, 6:1197-1202 (1988), and the only product observed was full length MDV-Fal-St ~`
05 (Figure 2, lanes 2-4). However, when enzyme prepared by the method of Eoyang and August was incubated under the same conditions as above, RNA synthesis was observed in the absence of added RNA template, indicating contamination of the enzyme preparation with MDV-l RNA. :
The resulting material was analyzed on a denaturing :
polyacrylamide gel, and as shown in Figure 3, MDV-l RNA
(Figure 3, lanes 1 and 2) was produced. Furthermore, when amplification reactions containing this enzyme were primed with 102 108 MDV-Fal-St molecules, both and ~ :
15 Fal-St MDV-l RNA were synthesized (Figure 3, lanes 3-6). .: -~
Equiv_lents Those skilled in the art will recognize, or be able ~ `~
to ascertain using no more than routine experimentation, -~ ~-many equivalents to the specific embodiments of the ~:
invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.
',
Claims (14)
1. Substantially pure Q Beta replicase.
2. Q Beta replicase substantially free of RNA.
3. Q Beta replicase substantially free of MDV RNA and Q
Beta RNA.
Beta RNA.
4. A method of producing substantially pure Q Beta replicase, comprising the steps of:
a) providing a lysate of Q Beta replicase-producing cells;
b) selectively separating nucleic acids from the cell lysate of (a), to form a Q Beta replicase-containing fraction of the cell lysate;
c) contacting the Q Beta replicase-containing fraction of step (b) with a cationic resin, under conditions appropriate for binding of Q
Beta replicase and the cationic resin, to form cationic resin-bound Q Beta replicase;
d) eluting Q Beta replicase from the cationic resin;
e) contacting eluted Q Beta replicase produced in step (d) with an anionic resin, under conditions appropriate for binding of Q Beta replicase and the anionic resin, to form anionic resin-bound Q Beta replicase; and f) eluting Q Beta replicase from the anionic resin.
a) providing a lysate of Q Beta replicase-producing cells;
b) selectively separating nucleic acids from the cell lysate of (a), to form a Q Beta replicase-containing fraction of the cell lysate;
c) contacting the Q Beta replicase-containing fraction of step (b) with a cationic resin, under conditions appropriate for binding of Q
Beta replicase and the cationic resin, to form cationic resin-bound Q Beta replicase;
d) eluting Q Beta replicase from the cationic resin;
e) contacting eluted Q Beta replicase produced in step (d) with an anionic resin, under conditions appropriate for binding of Q Beta replicase and the anionic resin, to form anionic resin-bound Q Beta replicase; and f) eluting Q Beta replicase from the anionic resin.
5. A method for purifying Q Beta replicase from cells in which it is produced, comprising the steps of:
a) disrupting cells which produce Q beta replicase to form a cell lysate;
b) contacting the cell lysate with polyethyleneimine under conditions appropriate for selective precipitation of nucleic acids present in the lysate, resulting in formation of a supernatant containing Q-beta replicase;
c) contacting the supernatant with a Q Sepharose resin, under conditions appropriate for binding of Q Beta replicase to the resin;
d) contacting the product of step (c) with a first elution buffer under conditions appropriate for separation of Q Beta replicase from the resin;
e) contacting the product of step (d) with an S
Sepharose resin, under conditions appropriate for binding of Q Beta replicase to the resin;
and f) contacting the resin of step (e) with a second elution buffer, under conditions appropriate for separation of Q Beta replicase from the resin.
a) disrupting cells which produce Q beta replicase to form a cell lysate;
b) contacting the cell lysate with polyethyleneimine under conditions appropriate for selective precipitation of nucleic acids present in the lysate, resulting in formation of a supernatant containing Q-beta replicase;
c) contacting the supernatant with a Q Sepharose resin, under conditions appropriate for binding of Q Beta replicase to the resin;
d) contacting the product of step (c) with a first elution buffer under conditions appropriate for separation of Q Beta replicase from the resin;
e) contacting the product of step (d) with an S
Sepharose resin, under conditions appropriate for binding of Q Beta replicase to the resin;
and f) contacting the resin of step (e) with a second elution buffer, under conditions appropriate for separation of Q Beta replicase from the resin.
6. A method of Claim 5, wherein the cells are E. coli cells which produce Q Beta replicase.
7. A method of Claim 5, wherein cells are disrupted in step (a) by sonication or homogenization.
8. A method of Claim 5, wherein step (c) is performed by contacting the cell lysate with polyethyleneimine.
9. A method of Claim 5, wherein the first elution buffer and the second elution buffer comprise salt gradients having a concentration of NaCl of from about 100 to about 400 mM.
10. A method of producing substantially pure Q Beta replicase, comprising the steps of:
a) providing a lysate of Q Beta replicase-producing E. coli cells;
b) contacting the cell lysate with a polyethyleneimine in the presence of NaClunder conditions appropriate for selective precipitation of nucleic acids present in the lysate, resulting in formation of a supernatant containing Q Beta replicase;
c) contacting the supernatant with a Q Sepharose resin under conditions appropriate for binding of Q Beta replicase to the resin;
d) contacting the product of step (c) with a first elution buffer under conditions appropriate for separation of Q Beta replicase from the resin;
e) contacting the product of step (d) with an S
Sepharose resin, under conditions appropriate for binding of Q Beta replicase to the resin;
and f) contacting the resin of step (e) with a second elution buffer, under conditions appropriate for separation of Q Beta replicase from the resin.
a) providing a lysate of Q Beta replicase-producing E. coli cells;
b) contacting the cell lysate with a polyethyleneimine in the presence of NaClunder conditions appropriate for selective precipitation of nucleic acids present in the lysate, resulting in formation of a supernatant containing Q Beta replicase;
c) contacting the supernatant with a Q Sepharose resin under conditions appropriate for binding of Q Beta replicase to the resin;
d) contacting the product of step (c) with a first elution buffer under conditions appropriate for separation of Q Beta replicase from the resin;
e) contacting the product of step (d) with an S
Sepharose resin, under conditions appropriate for binding of Q Beta replicase to the resin;
and f) contacting the resin of step (e) with a second elution buffer, under conditions appropriate for separation of Q Beta replicase from the resin.
11. A method of Claim 10, wherein the polyethyleneimine is 10% (w/v) polyethyleneimine.
12. Q Beta replicase produced by the method of Claim 4.
13. Q Beta replicase produced by the method of Claim 5.
14. Q Beta replicase of Claim 13, which is substantially free of MDV RNA and Q Beta RNA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/364,306 US5141857A (en) | 1989-06-09 | 1989-06-09 | Purification of q beta replicase |
| US364,306 | 1989-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2018566A1 true CA2018566A1 (en) | 1990-12-09 |
Family
ID=23433925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002018566A Abandoned CA2018566A1 (en) | 1989-06-09 | 1990-06-08 | Purification of q beta replicase |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5141857A (en) |
| EP (1) | EP0501949B1 (en) |
| JP (1) | JP3134934B2 (en) |
| CA (1) | CA2018566A1 (en) |
| DE (1) | DE68924601T2 (en) |
| WO (1) | WO1990015135A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464744A (en) * | 1992-09-24 | 1995-11-07 | Norval B. Galloway | Methods and compositions for reducing false positive signals in an RNA amplification system |
| US5622822A (en) * | 1994-09-13 | 1997-04-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using polyethyleneimine and an anionic phosphate ester surfactant and amplification of same |
| US6562575B1 (en) | 2000-06-26 | 2003-05-13 | Epicentre Technologies Corporation | Analyte-specific assays based on formation of a replicase substrate |
| WO2003064626A2 (en) * | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Double-stranded oligonucleotides |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| EP1572902B1 (en) * | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
| AU2003243541A1 (en) * | 2002-06-12 | 2003-12-31 | Ambion, Inc. | Methods and compositions relating to labeled rna molecules that reduce gene expression |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
| US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
| EP1736538A1 (en) * | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| AU2008222611A1 (en) * | 2007-03-06 | 2008-09-12 | Macquarie University | Vectors and methods for enzyme production |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3401617A1 (en) * | 1984-01-18 | 1985-07-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | RESTRICTIONSENDONUKLEASE MAE I, YOUR RECOVERY AND USE |
| US4786600A (en) * | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
| EP2843945B1 (en) | 2012-04-23 | 2020-03-11 | Sun Patent Trust | Image encoding method, image decoding method, image encoding device, image decoding device, and image encoding/decoding device |
-
1989
- 1989-06-09 US US07/364,306 patent/US5141857A/en not_active Ceased
- 1989-09-19 WO PCT/US1989/004092 patent/WO1990015135A1/en not_active Ceased
- 1989-09-19 JP JP03500890A patent/JP3134934B2/en not_active Expired - Fee Related
- 1989-09-19 EP EP89910740A patent/EP0501949B1/en not_active Expired - Lifetime
- 1989-09-19 DE DE68924601T patent/DE68924601T2/en not_active Expired - Fee Related
-
1990
- 1990-06-08 CA CA002018566A patent/CA2018566A1/en not_active Abandoned
-
1994
- 1994-08-18 US US08/292,574 patent/USRE35443E/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE68924601D1 (en) | 1995-11-23 |
| JPH04505859A (en) | 1992-10-15 |
| EP0501949A1 (en) | 1992-09-09 |
| EP0501949B1 (en) | 1995-10-18 |
| US5141857A (en) | 1992-08-25 |
| DE68924601T2 (en) | 1996-04-04 |
| JP3134934B2 (en) | 2001-02-13 |
| USRE35443E (en) | 1997-02-04 |
| WO1990015135A1 (en) | 1990-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5990302A (en) | Method for isolating ribonucleic acid | |
| EP0501949B1 (en) | Purification of q beta replicase | |
| US9481872B2 (en) | Nucleic acid-free thermostable enzymes and methods of production thereof | |
| Edmonds | Polyadenylate polymerases | |
| EP0037687A2 (en) | Recombinant deoxyribonucleid acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom | |
| KR20010034467A (en) | Improved method for the isolation of nucleic acid | |
| Haggård-Liungquist et al. | Bacteriophage P2: genes involved in baseplate assembly | |
| Zabel et al. | In vitro replication of cowpea mosaic virus RNA. II. Solubilization of membrane-bound replicase and the partial purification of the solubilized enzyme | |
| US4401759A (en) | Detection and isolation of glucagon mRNA using a synthetic oligodeoxynucleotide | |
| US3444042A (en) | Purified replicases and their uses | |
| JP3082908B2 (en) | Method for isolating ribonucleic acid | |
| Riedel et al. | Circular single stranded phage M13-DNA as a template for DNA synthesis in protein extracts from Xenopus laevis eggs: evidence for a eukaryotic DNA priming activity | |
| Young et al. | Tobacco mosaic virus replicase and replicative structures | |
| Amano | Metabolism of RNA in the liver cells of the rat I. Isolation and chemical composition of nucleus, nucleolus, chromatin, nuclear SAP and cytoplasm | |
| Aubertin et al. | Proteins of a Polyhedral Cytoplasmic Deoxyvirus: III. Structure of Frog Virus 3 and Location of Virus-Associated Adenosine Triphosphate Phosphohydrolase | |
| Erikson et al. | Structure and function of bacteriophage R17 replicative intermediate RNA: I. Studies on sedimentation and infectivity | |
| Hill et al. | Infectious viral DNA in Rous sarcoma virus-transformed nonproducer and producer animal cells | |
| Aoyama et al. | Effects of genome size on bacteriophage phi X174 DNA packaging in vitro. | |
| Gomatos | Reovirus-specific, single-stranded RNA's synthesized in vitro with enzyme purified from reovirus-infected cells | |
| CA2266853A1 (en) | Compositions and methods for rapid isolation of plasmid dna | |
| JPH04141098A (en) | RNA detection reagent and RNA detection method using the same | |
| Avadhani et al. | Poly adenylic acid sequences in mitochondrial RNA | |
| JP2002535412A (en) | Method for preparing endotoxin-free nucleic acids and uses thereof | |
| Geelen et al. | Properties of RNA polymerases of healthy and citrus exocortis viroid-infected Gynura aurantiaca DC | |
| Geider et al. | Gene-II protein of bacteriophage fd in enzymatic replication of viral duplex DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |